Research & Development

Sanofi establishes mRNA Center of Excellence to accelerate Covid-19 vaccines development

Global biopharmaceutical firm Sanofi has launched a dedicated vaccines mRNA Center of Excellence to accelerate development and delivery of next-generation vaccines.

AbbVie to acquire TeneoOne and multiple myeloma drug from Teneobio

AbbVie is set to acquire Teneobio affiliate TeneoOne and its lead drug candidate TNB-383B, which is being developed to treat relapsed or refractory multiple myeloma (R/R MM).

ViiV Healthcare, Halozyme partner to develop HIV medicines

ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV.

Arrowhead, Horizon sign collaboration deal for RNAi therapeutic development

Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH.

MorphoSys agrees to acquire Constellation Pharmaceuticals for $1.7bn

German company MorphoSys has signed a definitive agreement to acquire US-based Constellation Pharmaceuticals for approximately $1.7bn.

Pfizer acquires Amplyx Pharmaceuticals

Pharmaceutical company Pfizer has acquired a privately held company Amplyx Pharmaceuticals for an undisclosed amount.

NIAID grants $2.5m to 12 institutes for bacteriophage therapy research

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.

Bharat Biotech’s Phase III interim results of COVAXIN demonstrate efficacy of 81%

Biopharmaceutical company Ocugen has announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, which is a whole virion inactivated Covid vaccine candidate.

Boehringer Ingelheim, Gubra to validate new Peptides for obesity

Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity.